IL322741A - פורמולציות של אוליגומרים אנטיסנס - Google Patents
פורמולציות של אוליגומרים אנטיסנסInfo
- Publication number
- IL322741A IL322741A IL322741A IL32274125A IL322741A IL 322741 A IL322741 A IL 322741A IL 322741 A IL322741 A IL 322741A IL 32274125 A IL32274125 A IL 32274125A IL 322741 A IL322741 A IL 322741A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical formulation
- aso
- liquid composition
- kit
- concentration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363484890P | 2023-02-14 | 2023-02-14 | |
| US202463625171P | 2024-01-25 | 2024-01-25 | |
| PCT/US2024/015838 WO2024173582A2 (en) | 2023-02-14 | 2024-02-14 | Antisense oligomer formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL322741A true IL322741A (he) | 2025-10-01 |
Family
ID=92420749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL322741A IL322741A (he) | 2023-02-14 | 2024-02-14 | פורמולציות של אוליגומרים אנטיסנס |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4665407A2 (he) |
| JP (1) | JP2026507323A (he) |
| KR (1) | KR20250155076A (he) |
| CN (1) | CN121194802A (he) |
| AU (1) | AU2024222908A1 (he) |
| IL (1) | IL322741A (he) |
| MX (1) | MX2025009526A (he) |
| WO (1) | WO2024173582A2 (he) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113748209A (zh) | 2019-02-27 | 2021-12-03 | 斯托克制药公司 | 用于治疗病况和疾病的反义寡聚体 |
| KR20230022409A (ko) | 2020-05-11 | 2023-02-15 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 opa1 안티센스 올리고머 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2447052A1 (en) * | 2001-05-17 | 2002-11-21 | Avi Biopharma, Inc. | Combined approach to treatment of cancer using a c-myc antisense oligomer |
| CA3101321A1 (en) * | 2018-06-26 | 2020-01-02 | Nippon Shinyaku Co., Ltd. | Composition comprising antisense oligonucleotide and use thereof for treatment of duchenne muscular dystrophy |
| IL293531A (he) * | 2019-12-06 | 2022-08-01 | Stoke Therapeutics Inc | אוליגומרים אנטיסנס לטיפול במצבים ומחלות |
-
2024
- 2024-02-14 IL IL322741A patent/IL322741A/he unknown
- 2024-02-14 WO PCT/US2024/015838 patent/WO2024173582A2/en not_active Ceased
- 2024-02-14 EP EP24757634.1A patent/EP4665407A2/en active Pending
- 2024-02-14 JP JP2025546923A patent/JP2026507323A/ja active Pending
- 2024-02-14 CN CN202480025563.8A patent/CN121194802A/zh active Pending
- 2024-02-14 KR KR1020257030571A patent/KR20250155076A/ko active Pending
- 2024-02-14 AU AU2024222908A patent/AU2024222908A1/en active Pending
-
2025
- 2025-08-13 MX MX2025009526A patent/MX2025009526A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025009526A (es) | 2025-11-03 |
| WO2024173582A3 (en) | 2024-10-03 |
| EP4665407A2 (en) | 2025-12-24 |
| KR20250155076A (ko) | 2025-10-29 |
| WO2024173582A2 (en) | 2024-08-22 |
| AU2024222908A1 (en) | 2025-09-04 |
| JP2026507323A (ja) | 2026-03-02 |
| CN121194802A (zh) | 2025-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230116704A1 (en) | Antisense oligomers for treatment of conditions and diseases | |
| US20250243493A1 (en) | Compounds for treatment of conditions and diseases | |
| US6653466B2 (en) | Pharmaceutical composition for treatment of duchenne muscular dystrophy | |
| AU780517B2 (en) | Medicament for treatment of duchenne muscular dystrophy | |
| US11034962B2 (en) | Inhibitors of CACNA1A/ALPHA1A subunit internal ribosomal entry site (IRES) and methods of treating spinocerebellar ataxia type 6 | |
| GB2594767A (en) | Antisense oligomers for treatment of conditions and diseases | |
| JP2019500346A (ja) | 腎臓病の処置のための組成物と方法 | |
| KR20220084437A (ko) | 대상에게서 smn2 스플라이싱을 조정하기 위한 조성물 및 방법 | |
| WO2024173582A2 (en) | Antisense oligomer formulations | |
| JP2002325582A (ja) | デュシェンヌ型筋ジストロフィー治療剤 | |
| US20250066781A1 (en) | Methods for treating conditions and diseases | |
| WO2025199503A1 (en) | Methods for treating conditions and diseases | |
| WO2025024568A1 (en) | Methods for treating conditions and diseases | |
| JP2025519571A (ja) | 一遺伝子性神経発達障害の治療のための組成物及び方法 | |
| AU2023329830A1 (en) | Engineered constructs for increased transcription of rna payloads | |
| US20250283086A1 (en) | Compositions and methods for treatment of kidney disease | |
| HK40064034A (en) | Antisense oligomers for treatment of conditions and diseases |